Table 2 Crude and adjusted rate ratios for the association between the use of cardiac glycosides and lung cancer incidence
From: Cardiac glycosides use and the risk of lung cancer: a nested case–control study
Exposure to cardiac glycosides | Cases | Controls | Crude RR | Adjusted RR (95% CI)a |
|---|---|---|---|---|
(n = 1237) | (n = 12,320) | |||
Overall | ||||
No use, n (%) | 860 (69.5) | 8528 (69.2) | 1.00 | 1.00 (Reference) |
Ever use, n (%) | 377 (30.5) | 3792 (30.8) | 0.98 | 1.09 (0.94 - 1.26) |
Cumulative duration of use | ||||
<14 months, n (%) | 102 (8.2) | 962 (7.8) | 1.04 | 1.14 (0.91 - 1.45) |
14 - 32 months, n (%) | 102 (8.2) | 931 (7.6) | 1.10 | 1.21 (0.96 - 1.54) |
32 - 60 months, n (%) | 84 (6.8) | 927 (7.5) | 0.89 | 0.97 (0.75 - 1.25) |
> 60 months, n (%) | 89 (7.2) | 972 (7.9) | 0.89 | 0.99 (0.76 - 1.29) |
Cumulative dose (in digoxin-equivalents) | ||||
< 60 mg, n (%) | 121 (9.8) | 1109 (9.0) | 1.08 | 1.17 (0.94 - 1.45) |
60 - 120 mg, n (%) | 85 (6.9) | 746 (6.1) | 1.14 | 1.24 (0.96 - 1.59) |
120 - 240 mg, n (%) | 88 (7.1) | 880 (7.1) | 0.99 | 1.08 (0.84 - 1.39) |
>240 mg, n (%) | 83 (6.7) | 1057 (8.6) | 0.76 | 0.85 (0.65 - 1.11) |